Please login to the form below

Not currently logged in

Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline

Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology

Scribe Therapeutics has completed an oversubscribed $100m Series B financing round to advance the development of its CRISPR platform and pipeline.

Scribe was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology and co-recipient of the 2020 Nobel Prize in Chemistry.

The company’s platform is based on CRISPR technology (also known as CRISPR-Cas9) – CRISPRs are specialised stretches of DNA that can be cut by Cas9 enzymes.

This technology evolved from the natural defence mechanisms of bacteria and archaea, which use RNA and Cas proteins to target and attack viruses and other foreign bodies.

Scribe’s technology platform can create custom CRISPR molecules that are specifically designed for therapeutic use within the body, overcoming the limitation of using existing enzymes that may lead to ‘poor editing outcomes’.

“Scribe’s engineering-first philosophy has resulted in a uniquely flexible platform for imagining and creating a new era of CRISPR-based therapies to elevate the standard of care for thousands of patients,” said Jennifer Doudna, co-inventor of CRISPR technology, Nobel Laureate and co-founder of Scribe Therapeutics.

Scribe has already engineered CRISPR enzymes found in nature into millions of novel variants, which it says have ideal therapeutic attributes to enable ‘highly effective and specific in vivo applications’.

It is also looking to engineer additional technologies as part of its expanding platform while developing its pipeline to target areas of unmet need.

The company is already conducting a $400m research collaboration with Biogen to develop CRISPR-based therapies for Amyotrophic Lateral Sclerosis (ALS).

Scribe is also exploring additional therapeutic targets, as well as new partnership opportunities, the company said in a statement.

“We are building a future where treating the underlying causes of disease will be achieved by best-in-class, custom engineered technologies,” said Benjamin Oakes, chief executive officer and co-founder of Scribe Therapeutics.

“With molecular engineering at our core, we aim to move beyond discovery towards scalable biological design that can precisely address previously intractable genetic maladies,” he added.

Article by
Lucy Parsons

1st April 2021

From: Research



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....